Solana Co (HSDT) Stock Price & Analysis
Solana Co (HSDT) fell 4.12% to USD 1.63 as of July 25, 2026 at 15:00 UTC, according to Nexqual real-time market data.
HSDT last closed at USD 1.7; the session ranged USD 1.63–1.69 on volume of 120,590 shares. Market capitalization is $95.17M, with a 52-week range of USD 1.19–25.5 (NCM). Source: Nexqual, July 25, 2026 at 15:00 UTC.
Key Statistics (as of July 25, 2026 at 15:00 UTC)
| Price | USD 1.63 |
|---|---|
| Change | ▼ 4.12% (down) |
| Previous Close | USD 1.7 |
| Open | USD 1.68 |
| Day Range | USD 1.63 – 1.69 |
| 52-Week Range | USD 1.19 – 25.5 |
| Volume | 120,590 shares |
| Market Cap | $95.17M |
| Exchange | NCM |
Technical Analysis (HSDT)
Nexqual's technical model rates HSDT "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 15:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.21 (neutral) |
| vs SMA50 | Below (USD 1.78) |
| MACD | -0.01 (negative) |
Analyst Ratings (HSDT)
Wall Street analysts rate HSDT "None" based on 2 analysts, with a mean price target of USD 3.5 (range USD 3–4), per Nexqual as of July 25, 2026 at 15:00 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 3.5 |
| High Target | USD 4 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (HSDT)
| EPS Estimate | USD -0.02 |
|---|---|
| Revenue Estimate | $3.50M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.3 vs est -0.84 ▼ miss |
| 2025-09-30 | USD -32.89 vs est -50.5 ▲ beat |
| 2025-06-30 | USD -79.73 vs est -128.5 ▲ beat |
Source: Nexqual, July 25, 2026 at 15:00 UTC.
Financials & Fundamentals (HSDT)
| Total Revenue | $9.59M |
|---|---|
| Revenue Growth (YoY) | +7289.80% |
| Gross Margin | +94.17% |
| Operating Margin | -2751.12% |
| Profit Margin | +0.00% |
| ROE | -137.42% |
| Current Ratio | 9.9 |
| Total Cash | $4.39M |
| Total Debt | $0 |
| Free Cash Flow | $-345.50M |
Source: Nexqual, July 25, 2026 at 15:00 UTC.
Financial Health Score (HSDT)
Nexqual rates Solana Co's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 15:00 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $4M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$18M |
| Efficiency | Critical — ROE -137%, ROA -207.8% |
Ownership (HSDT)
| Insider Ownership | +22.26% |
|---|---|
| Institutional Ownership | +28.21% |
| Shares Outstanding | 58.39M |
| Float | 40.33M |
| Short % of Float | +2.26% |
Source: Nexqual, July 25, 2026 at 15:00 UTC.
Leadership (HSDT)
Solana Co is led by Choon Wee Chee (age 53), CEO, President & Chairman, per Nexqual as of July 25, 2026 at 15:00 UTC.
| CEO, President & Chairman | Choon Wee Chee (age 53) |
|---|---|
| COO, CFO Treasurer & Secretary | Agustina Gani Tjandrasuwita (age 49) |
Major Backers & Investors (HSDT)
Notable institutional backers of Solana Co include Kathmere Capital Management, Llc, Pantera Capital Partners LP, Yorkville Advisors Global, LP, according to Nexqual as of July 25, 2026 at 15:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kathmere Capital Management, Llc | 7.87% |
| Pantera Capital Partners LP | 6.66% |
| Yorkville Advisors Global, LP | 1.86% |
| Arrington Capital Management, LLC | 1.13% |
| Vr Advisory Services Ltd | 1% |
| LPL Financial LLC | 0.94% |
| Hel Ved Capital Management Ltd | 0.75% |
| Rockefeller Capital Management L.P. | 0.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.79% |
| Geode Capital | 0.63% |
Source: Nexqual, July 25, 2026 at 15:00 UTC.
From Solana Co's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Solana Company operates as a listed digital asset treasury.
- The company enhances Solana tokens per share on the commercially viable blockchain for decentralized finance and consumer applications.
- In addition, the company offers Portable Neuromodulation Stimulator, a non-implantable medical device, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHIO | Phio Pharmaceuticals Corp. | USD 1.04 | ▼ 1.89% |
| SPRC | SciSparc Ltd. | USD 5.33 | ▲ 10.12% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.28 | ▼ 2.17% |
| NUWE | Nuwellis, Inc. | USD 2.05 | ▼ 28.07% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.78 | ▲ 2.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:00 UTC. This page is informational and not investment advice.